H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $30 from $48 and keeps a Buy rating on the shares. The firm dropped the stock’s valuation multiples to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: